RYE, N.Y., Aug. 16 Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company will present at the Rodman & Renshaw Annual Global Investment Conference, scheduled for September 12-15 at the New York Palace Hotel in New York City.
Dr. Joan Fallon, Curemark's founder and CEO, will update investors on the progress of the company's clinical research for CM-AT, its autism treatment in development. She will also discuss the Investigational New Drug (IND) authorization Curemark recently received from the FDA for CM - 4612 to treat attention deficit hyperactivity disorder (ADHD). The U.S. Food and Drug Administration (FDA) has given clearance to Curemark's Investigational New Drug (IND) application for a Phase III clinical trial for the use of CM - 4612 in the treatment of attention deficit hyperactivity disorder (ADHD).
"We are very happy to have this opportunity to present at the Rodman & Renshaw annual investment conference. Curemark has achieved a variety of major milestones that we are looking forward to sharing with attendees," Fallon said.
CM-AT, Curemark's autism treatment, addresses enzyme deficiencies in autistic children which affect the availability of amino acids, the building blocks of chemicals essential for brain function. Phase III clinical trials are underway at 13 sites nationwide for CM-AT, which has received Fast Track status from the FDA. If approved, it will be one of the first therapies to address the underlying physiology of autism.
Curemark's presentation is part of the 12th annual healthcare conference, an industry track that will be showcased during the Rodman & Renshaw Annual Global Investment Conference. In addition to healthcare, the conference will highlight industry tracks including China, metals and mining, energy, technology, cleantech, community and regional banks, and REITs.
About CUREMARK LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.
Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
SOURCE Curemark, LLC